Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/jitc-2020-000898 http://scihub22266oqcxt.onion/10.1136/jitc-2020-000898 32434789!7246106!32434789     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Immunother+Cancer 2020 ; 8 (1): ä Nephropedia Template TP {{tp|p=32434789|t=2020. Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy |pdf=|usr=}}{{32434789}} gab.com Text Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy JO: J Immunother Cancer http://www.kidney.de/pget.php?&tw=1&pmid=32434789 #FOAvip BACKGROUND: Immune checkpoint inhibitors (ICIs) can produce specific immune-related adverse events including pneumonitis. The impact of ICI therapy on the severity of acute coronavirus infection symptomatology warrants further exploration. CASE PRESENTATION: We report a 65-year-old man diagnosed with stage IV melanoma who developed pulmonary and brain metastases and was treated with bilateral craniotomies followed by combined nivolumab and ipilimumab immunotherapy. He developed early-onset severe dyspnea associated with acute coronavirus HKU1 (non-COVID-19) infection, with diffuse pneumonitis evidenced by ground glass opacification on CT scan. He was treated with steroids leading to resolution of pneumonitis on repeat imaging, suggesting an exacerbated immune-mediated toxicity. CONCLUSION: We report the first case of a patient with melanoma with severe and reversible diffuse pneumonitis in association with coronavirus HKU1 following combined nivolumab and ipilimumab immunotherapy. Although we do not have data on the impact of ICI therapy on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) symptomatology, a possible interaction should be considered when deciding on dosing in patients with possible SARS-CoV-2 exposure or when evaluating patients with presumed ICI-related pneumonitis during the COVID-19 pandemic. Twit Text FOAVip Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy ????J Immunother Cancer http://www.kidney.de/pget.php?&tw=1&pmid=32434789 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32434789 #FOAvip English Wikipedia <ref>{{Cite pmid|32434789}}</ref> Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy #MMPMID32434789 Serzan MT; Kumar PN; Atkins MB J Immunother Cancer 2020[May]; 8 (1): ä PMID32434789show ga BACKGROUND: Immune checkpoint inhibitors (ICIs) can produce specific immune-related adverse events including pneumonitis. The impact of ICI therapy on the severity of acute coronavirus infection symptomatology warrants further exploration. CASE PRESENTATION: We report a 65-year-old man diagnosed with stage IV melanoma who developed pulmonary and brain metastases and was treated with bilateral craniotomies followed by combined nivolumab and ipilimumab immunotherapy. He developed early-onset severe dyspnea associated with acute coronavirus HKU1 (non-COVID-19) infection, with diffuse pneumonitis evidenced by ground glass opacification on CT scan. He was treated with steroids leading to resolution of pneumonitis on repeat imaging, suggesting an exacerbated immune-mediated toxicity. CONCLUSION: We report the first case of a patient with melanoma with severe and reversible diffuse pneumonitis in association with coronavirus HKU1 following combined nivolumab and ipilimumab immunotherapy. Although we do not have data on the impact of ICI therapy on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) symptomatology, a possible interaction should be considered when deciding on dosing in patients with possible SARS-CoV-2 exposure or when evaluating patients with presumed ICI-related pneumonitis during the COVID-19 pandemic. |Aged[MESH] |Antineoplastic Combined Chemotherapy Protocols/therapeutic use[MESH] |Coronavirus Infections/diagnostic imaging/*drug therapy[MESH] |Coronavirus/isolation & purification[MESH] |Humans[MESH] |Immunotherapy[MESH] |Ipilimumab/administration & dosage[MESH] |Male[MESH] |Melanoma/*drug therapy/virology[MESH] |Nivolumab/administration & dosage[MESH] |Pneumonia, Viral/diagnostic imaging/*drug therapy/virology[MESH]Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor ther(epmc).pdf DeepDyve Pubget Overpricing